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Abstract
Background: Improved recognition of factors influencing graft survival has led to better short-term kidney
transplant outcomes. However, efforts to prevent long-term graft decline and improve graft survival have seen
more modest improvements. The adoption of electronic health records has enabled better recording and
identification of donor-recipient factors through the use of modern statistical techniques. We have previously
shown in a prevalent renal transplant population that episodes of rapid deterioration are associated with graft loss.
Methods: Estimated glomerular filtration rates (eGFR) between 3 and 27 months after transplantation were
collected from 310 kidney transplant recipients. We utilised a Bayesian approach to estimate the most likely eGFR
trajectory as a smooth curve from an average of 10,000 Monte Carlo samples. The probability of having an episode
of rapid deterioration (decline greater than 5 ml/min/1.73 m2 per year in any 1-month period) was calculated. Graft
loss and mortality data was collected over a median follow-up period of 8 years. Factors associated with having an
episode of rapid deterioration and associations with long-term graft loss were explored.
Results: In multivariable Cox Proportional Hazard analysis, a probability greater than 0.8 of rapid deterioration was
associated with long-term death-censored graft loss (Hazard ratio 2.17; 95% Confidence intervals [CI] 1.04–4.55). In
separate multivariable logistic regression models, cytomegalovirus (CMV) serostatus donor positive to recipient
positive (Odds ratio [OR] 3.82; 95%CI 1.63–8.97), CMV donor positive (OR 2.06; 95%CI 1.15–3.68), and CMV recipient
positive (OR 2.03; 95%CI 1.14–3.60) were associated with having a greater than 0.8 probability of an episode of
rapid deterioration.
Conclusions: Early episodes of rapid deterioration are associated with long-term death-censored graft loss and are
associated with cytomegalovirus seropositivity. Further study is required to better manage these potentially
modifiable risks factors and improve long-term graft survival.
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Background
The last three decades have seen a remarkable improve-
ment in renal transplant survival, a product of techno-
logical advances in surgical technique and medical care.
In particular, the availability of novel and potent im-
munosuppressive drugs has been paralleled by strategies
to reduce immunosuppression-related toxicity and op-
portunistic infections [1]. In addition to improving graft
survival, maintenance of transplant graft function, or
glomerular filtration rate, is another key strategy to min-
imise the complications associated with advanced
chronic kidney disease (CKD) and improve patient sur-
vival [1, 2]. Deterioration in renal transplant function re-
mains a significant issue, and ranks amongst the top
four causes of end-stage renal disease (ESRD) in the
United States [3]. Kidney transplant recipients rank
transplant survival the most important outcome [4]. Al-
though early outcomes after kidney transplantation have
improved markedly over the last couple of decades, im-
provements in long-term outcomes have been much
more modest [1, 5]. The major factors for graft loss are
well established and usually reflect patient and donor
characteristics at the time of transplantation (e.g. donor
age, immunological mismatch) that are essentially non-
modifiable [6]. However, potentially modifiable risk fac-
tors including cytomegalovirus (CMV) serostatus/mis-
match are emerging as possible therapeutic targets [7].
The increasing adoption of Electronic Health Record
(EHR) systems in recent years [8] has resulted in the ac-
cumulation of a massive amount of structured data on
patients and their disease deterioration. It has been ar-
gued that that the quality of care of CKD and kidney
transplant recipients could be improved by effective util-
isation of EHR [9]. However, most studies examining
change in renal function have been fairly simplistic and
assume a linear decline [10, 11]. Furthermore, prior sur-
vival analyses have tended to rely on single baseline
timepoint measurements, without consideration for fluc-
tuations of the measurement over time and how these
impact on the outcome during the observation period.
Alternatively, repeated measurements of parameters, for
example estimated glomerular filtration rate (eGFR), al-
lows quantification of the variability and provide a better
estimation of the true trajectory over time. The trajec-
tory and the nature of the variability can then be used to
explore associations with outcomes of interest [12].
Although there has been an increased interest in
examining renal function trajectories in CKD [13, 14],
there is little work in kidney transplantation [15]. Work
from CKD groups and our own in renal transplant recip-
ients [16] suggest that most patients do not experience
linear renal function. Instead, many experience periods
of non-progression and episodes of rapid decline. We
have previously shown in a prevalent kidney transplant
population that episodes of rapid deterioration of renal
function were frequent and more likely in patients who
subsequently lost their grafts [16]. Whether this is true
in incident patients is unknown. Understanding the tra-
jectories of kidney allograft (dys) function, especially in
the early post-transplantation period, is key to under-
standing mechanisms behind graft dysfunction and sub-
sequent failure, and the implementation of preventative
strategies.
The purpose of this study was threefold:
1. Investigate the probability of episodes of rapid
deterioration of renal function in an early period
(3–27 months) post-transplantation in an unse-
lected, incident population of kidney allograft
recipients.
2. Evaluate baseline factors associated with an episode
of rapid deterioration of eGFR during the early (3–
27months) period post-transplantation.
3. Probe whether episodes of rapid deterioration of
renal function during the early (3–27 months)
period post-transplantation are associated with sub-
sequent graft loss in an extended follow-up period.
Methods
Study population
We used a comprehensive database, created by data
linkage between a number of EHR, of all adult patients
aged 18 or over with ESRD who received a kidney-only
transplant at our centre between 21st January 2007 and
31st December 2013. Data for every study participant
were extracted from the Department of Health Informat-
ics database, with manual record linkage to additional
EHR: graft survival was acquired from the UK Trans-
plant Registry held by NHS Blood and Transplant; pa-
tient survival data were obtained from the Office for
National Statistics. Patients were included if they
remained under our follow-up and were not repatriated
to their original referring hospital post-transplantation,
and were alive with a working graft 27 months after
transplantation. Patients with missing donor and/or re-
cipient CMV data were excluded. Patients were classified
based on CMV serostatus: donor and recipient seronega-
tive (D−/R−), donor seronegative and recipient seroposi-
tive (D−/R+), donor seropositive and recipient
seronegative (D+/R−), and donor and recipient seroposi-
tive (D+/R+). Survival analysis was censored to event or
31st November 2018, whichever occurred first.
We utilised existing ethnicity classifications as ob-
tained from EHR, which were cross-checked against UK
Transplant Registry data. Ethnicity was classified into
white, black, south Asian (also referred to as Indo-
Asian) or other.
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Determination of socioeconomic deprivation was
based on the Index of Multiple Deprivation (IMD), a
composite score encompassing multiple domains reflect-
ive of areas of socioeconomic deprivation. The IMD
scores are divided into quintiles, 1 represents the most
deprived and 5 represents the least deprived area.
Immunosuppression and Cytomegalovirus prophylaxis
protocol
All patients received the same immunosuppression in
line with the SYMPHONY protocol over the study
period. Induction therapy was with basiliximab 10mg
twice/day and methylprednisolone 500 mg on the day of
transplantation. Maintenance therapy included tacroli-
mus (target 12-h trough level: 5−8 ng/L), mycophenolate
mofetil (2 g/day with tapering to 1 g/day after 6 months),
and prednisolone. Patients who were deemed high risk
(D+/R−) received 3 months of valganciclovir post-
transplant.
Assessment of an episode of rapid deterioration in the
estimated glomerular filtration rate trajectory
All eGFR values up to 27 months after transplantation
were retrieved. Values in the first 3 months post-
transplantation were excluded because of the intrinsic
variability of renal function in the immediate post-
transplantation period giving 24 months of values for
analysis. We used a Bayesian smoothing technique to es-
timate each patient’s eGFR trajectory as a smooth curve
in the observation [16]. This technique produces a
smooth curve for each individual patient that reflects the
more gradual, longer-term changes in eGFR values, ra-
ther than the more rapid, short-term changes because of
clinical and biologic variation as well as other interfer-
ence including measurement error. The smoothness of
the curve was determined automatically by the data
based on the prespecified model. For each individual pa-
tient, the Bayesian approach produced 10,000 Monte
Carlo samples to approximate the posterior distribution
of all modelling parameters, which led to 10,000 curves
that quantified the uncertainty in the true trajectory
given the variation of the data. Under the Bayesian ap-
proach we estimated the “most-likely” trajectory by the
average of those 10,000 Monte Carlo curves. The Bayes-
ian approach allows estimation of the probability that a
patient’s trajectory had a feature of interest as a propor-
tion of the 10,000 Monte Carlo curves that showed this
feature. The estimated trajectory is a smooth curve,
allowing its slope to be calculated month by month, ac-
commodating a possible change in rate of deterioration
over time.
We calculated the probability of a period of rapid de-
terioration of renal function as an eGFR trajectory hav-
ing at least 1 month in which eGFR declined by at least
5 mL/min/1.73 m2 per year. This is the threshold con-
ventionally used in CKD guidelines to define a rapid de-
cline in renal function [17]. Patients were considered to
have had at least 1 period of rapid deterioration if the
probability was ≥0.8. Sensitivity analyses were conducted
using probabilities ≥0.70 and 0.90.
Statistical analysis
Continuous data are expressed as mean ± standard devi-
ation for parametric data or median (25th–75th quar-
tiles) for nonparametric data, and compared using
Student t-test or Mann-Whitney U test respectively. Cat-
egorical data are presented as percentages and compared
using the chi-square or Fisher’s exact tests.
Our outcomes of interest were having a probability of
rapid deterioration of renal function ≥0.8 in the 2-year
observation period (3–27months post-transplant) and
graft and patient survival during the follow-up period
(27 months post-transplant until data censored). Graft
failure was taken as the time from transplant to return
to dialysis, graft nephrectomy, or repeat kidney trans-
plant (whichever occurred first, with death data cen-
sored). Patient survival was defined as the time from
transplant until death.
Logistic regression analysis was used to model the bin-
ary outcome of having a probability of rapid deterior-
ation of renal function ≥0.8 in the observation period
and Cox proportional hazards regression models were
used for time-to-event outcome analysis for graft loss
and all-cause mortality. For graft survival and all-cause
mortality, Kaplan-Meier analyses were run with Mantel-
Cox (log-rank) tests used to compare patient groups and
to test the proportionality hazards assumption. Covari-
ates included in the multivariable analyses were any with
P < 0.10 in unadjusted analyses. Closely-correlated fac-
tors (e.g. CMV serostatus combinations, CMV D+ and
CMV R+) were entered one at a time into separate mul-
tivariable models. Transplant outcomes were compared
using D−/R− as reference. A separate model which in-
cluded only recipients with CMV seropositive donors
(D+/R− vs D+/R+; using D+/R− as a reference group)
was analysed. Models were tested using backward and
forward entry methods. Data was 100% complete for all
covariates and outcomes of interest.
Analyses were performed using R 3.5.1 (R Foundation,




Eight hundred and one incident, unselected adult (≥18
years) kidney transplants were performed in our centre
over the study period. Of these, 106 (13%) lost their graft
within 27 months of transplantation. Three hundred and
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fifty patients were repatriated to their referring unit and
therefore excluded. A further 35 subjects were excluded
for having incomplete CMV serostatus recorded leaving
310 patients in the analyses (Fig. 1). Overall median time
post-transplant was 8.0 years (Interquartile range [IQR]
6.6–9.7 years) giving an overall median follow-up period
of 5.7 years (IQR 4.4–7.5 years) after the initial 27
months of data collection were excluded. The median
number of eGFR measurements available for analysis
from 3months to 27months after transplantation was
54 (IQR 36–82) with the minimum being 16
measurements.
Probability of having an episode of rapid deterioration in
months 3–27 after kidney transplantation
Figure 2a and b show example trajectory plots for indi-
vidual patients with probabilities of having an episode of
rapid deterioration of 1.0 and 0 respectively. The distri-
bution of probability of a period of rapid deterioration is
shown in Fig. 3. Sixty-five patients (21%) had a
probability of rapid deterioration ≥0.8 and 90 (29%) had
a probability ≥0.5. The clinical demographics of the pa-
tients classified as having, or not having ≥0.8 probability
of a period of rapid deterioration of renal function are
presented in Table 1. Other than CMV serostatus
groups, there were only minimal differences between the
two groups, and none were statistically significant.
Whereas all four CMV serostatus groups were roughly
equally represented in patients without rapid deterior-
ation, significantly more patients with a probability of
rapid deterioration ≥0.8 were D+/R+ (46%) than D−/R−
(12%; P = 0.01). Patients with a probability of rapid de-
terioration ≥0.8 were more likely to be CMV seroposi-
tive (CMV+) at the time of transplantation (66.2% vs
48.6%; P = 0.012) and more likely to receive a kidney
from a CMV+ donor (67.7% vs 50.6%, P = 0.017) than
patients without rapid deterioration of renal function.
Using different cut-offs of probability of rapid deterior-
ation ≥0.7 and 0.9 did not materially affect the results
(Supplementary Table 1a and b).
Fig. 1 Flow diagram showing numbers and reasons for patients included and excluded in this study
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Factors associated with having an episode of rapid
deterioration
Univariable and adjusted associations with having a
probability of rapid deterioration ≥0.8 are shown in Sup-
plementary Table 2. In separate multivariable analyses,
only CMV D+/R+ (Odds ratio [OR] 3.86; 95% confi-
dence intervals [CI] 1.65–9.03; P = 0.002: ref. D−/R−),
Donor CMV+ (OR 2.05; 95%CI 1.15–3.64; P = 0.015: ref.
Donor CMV seronegative [CMV−]) and Recipient
CMV+ (OR 2.07; 95%CI 1.17–3.66; P = 0.013: ref. Re-
cipient CMV-) were significantly associated with a prob-
ability ≥0.8 of having an episode of rapid deterioration of
renal function, and were independent of renal function
when individually adjusted for eGFR at 27 months. Re-
sults were materially unchanged if different cut-offs of
probability of rapid deterioration ≥0.7 and 0.9 were used
(Supplementary Table 3).
Death-censored graft loss
A total of 34 (10.9%) of patients lost their graft and ei-
ther started dialysis or were re-transplanted during the
follow-up period. The death-censored graft survival
curve for patients with and without a ≥ 0.8 probability of
an episode of rapid deterioration of renal function is
shown in Fig. 4. Although graft loss appeared to be
higher in patients (16.9% v. 9.4%) with an episode of
rapid deterioration, this did not achieve statistical signifi-
cance (log-rank test P = 0.071) in univariable analysis.
The full univariable associations with death-censored
graft loss are shown in Supplementary Table 4.
In multivariable Cox regression modelling, having a
probability ≥0.8 of an episode of rapid deterioration of
renal function (Hazard ratio [HR] 2.38; 95%CI 1.14–
Fig. 2 a shows an average trajectory with probability close to 1 of
rapid deterioration. b shows an average trajectory with probability
close to 0 of rapid deterioration. The horizontal axis is months since
transplantation and the vertical axis is estimated glomerular filtration
rate (eGFR; ml/min/1.73m2). (blue dots) eGFR data. (red smooth
curve) The estimated trajectory
Fig. 3 The distribution of probabilities of rapid deterioration visualised by percentage frequency histograms
Law et al. BMC Nephrology          (2021) 22:102 Page 5 of 11
Table 1 Comparison of baseline characteristics between groups on estimated glomerular filtration rate trajectories. The presence of
an episode of rapid deterioration is based on more than 80% of curves displaying this characteristic. The number (percentage) or
mean (standard deviation) or median (25th, 75th quartiles) are reported for each subgroup. The median (range) is reported for the
number of eGFR measurements
Rapid Deterioration P-
valueNo (n = 245) Yes (n = 65)
Age (years) 45.73 ± 12.96 46.65 ± 14.36 0.622
Male 110 (45%) 25 (39%) 0.400
Race,
White 168 (68.6%) 49 (75.4%) 0.778
Asian 50 (20.4%) 9 (13.8%)
Black 15 (6.1%) 4 (6.2%)
Other 12 (4.9%) –
BMI (kg/m2) 27.14 (23.44, 30.94) 27.63 (24.00, 31.74) 0.379
Diabetes mellitus 22 (9%) 9 (14%) 0.249
Time on transplant waiting (days) 410 (213–1395) 656 (257–1407) 0.187
IMD
1 92 (37.6%) 21 (32.8%) 0.825
2 44 (18.0%) 11 (17.2%)
3 53 (21.6% 18 (28.1%)
4 24 (9.8%) 7 (10.9%)
5 32 (13.1%) 7 (10.9%)
Mean Number of HLA-mismatches 2.80 ± 1.53 2.67 ± 1.37 0.553
NODAT 15 (6.2%) 5 (7.7%) 0.777
Transplant Number
First 216 (88.2%) 59 (90.8%) 0.720
Second 21 (8.6%) 6 (9.2%)
Third 5 (2.0%) 0 (0%)
Donor Type
Cadaveric 119 (49%) 38 (58%) 0.165
Live 126 (51%) 27 (42%)
Donor age (years) 44.99 ± 13.29 48.08 ± 13.97 0.110
Male Donor 104 (52%) 31 (54%) 0.765
Donor Race
White 202 (82.4%) 60 (92.3%) 0.252
Asian 13 (5.3%) 1 (1.5%)
Black 26 (10.6%) 3 (4.6%)
Other 4 (1.6%) 1 (1.5%)
Donor BMI (kg/m2) 25.82 (23.02, 28.50) 25.35 (23.29, 28.56) 0.863
CMV Serostatus Combinations
D−/R− 69 (28%) 8 (12%) 0.010
D−/R+ 57 (23%) 14 (22%)
D+/R− 52 (21%) 13 (20%)
D+/R+ 67 (27%) 30 (46%)
CMV D+ 124 (50.6) 44 (67.7%) 0.017
CMV R+ 119 (48.6%) 43 (66.2%) 0.012
Acute rejection in first year 30 (12.4%) 12 (18.5%) 0.206
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4.98; P = 0.022), eGFR at 27 months (HR 0.95; 95%CI
0.93–0.98; P = 0.002) and recipient age (HR 0.94; 95%CI
0.91–0.97; P < 0.001) were significantly associated with
death-censored graft-loss. Inclusion of these factors re-
sulted in good model fit versus null model (model coeffi-
cient: Chi-square 45.544, p < 0.001 for rapid
deterioration ≥0.8). Model fit was not materially differ-
ent if eGFR at 12 months was inserted into the model or
if different cut-offs of probability of rapid deterioration
≥0.7 and 0.9 were used (model coefficient: Chi-square
48.100, p < 0.001 and Chi-square 47.207, p < 0.001 ver-
sus null model for rapid deterioration ≥0.7 and 0.9, re-
spectively) (Supplementary Table 5a and b).
All-cause mortality
A total of 43 (13.9%) of patients died during the follow-
up period. Of these 10 had a probability of an episode of
rapid deterioration of renal function greater than 0.8
and 30 did not (P = 0.689). The full univariable associa-
tions with all-cause mortality are shown in Supplemen-
tary Table 6. Having a probability of rapid deterioration
(HR 1.22; 95%CI 0.60–2.48; P = 0.578) greater than 0.8
was not associated with all-cause mortality. In multiple
regression models, only recipient age (HR 1.07; 95%CI
1.03–1.11; P = 0.001) and eGFR at the beginning of the
follow-up period (HR 0.97; 95%CI 0.95–1.00: P = 0.028)
remained significantly associated with all-cause mortal-
ity. Results were materially unchanged using cut-offs of
probability ≥0.7 or 0.9 for rapid deterioration (Supple-
mentary Table 7).
Discussion
We have previously shown in a prevalent renal trans-
plant recipient cohort that an episode of rapid deterior-
ation of renal function is associated with subsequent
graft loss [16]. In this study we extend these findings,
Table 1 Comparison of baseline characteristics between groups on estimated glomerular filtration rate trajectories. The presence of
an episode of rapid deterioration is based on more than 80% of curves displaying this characteristic. The number (percentage) or
mean (standard deviation) or median (25th, 75th quartiles) are reported for each subgroup. The median (range) is reported for the
number of eGFR measurements (Continued)
Rapid Deterioration P-
valueNo (n = 245) Yes (n = 65)
Delayed graft function 109 (44.5%) 22 (38.5%) 0.402
Number of eGFR measurements 54 (35.0, 83.5) 54 (39.0, 79.5) 0.929
eGFR (ml/min/1.73 m2)
3 months 54.63 ± 19.11 54.31 ± 22.27 0.905
12months 53.07 ± 20.49 51.92 ± 17.28 0.683
27months 51.67 ± 19.52 46.71 ± 15.98 0.091
BMI Body mass index, CMV Cytomegalovirus, D− donor CMV seronegative, D+ Donor CMV seropositive, eGFR Estimated glomerular filtration rate, IMD Index of
multiple deprivation, NODAT New onset diabetes after transplantation, R-− Recipient CMV seronegative, R+ Recipient CMV seropositive
Fig. 4 Death-censored Kaplan-Meier graft survival analysis for patients with and without a≥ 0.8 probability of an episode of rapid deterioration
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using the same Bayesian smoothing technique, to show
that in an unselected, incident renal transplant cohort,
an early episode of rapid deterioration is associated with
death-censored graft loss in multivariable regression
models. Furthermore, our findings demonstrate that
CMV seropositivity is associated with episodes of rapid
deterioration of renal function raising the possibility of a
mechanism that could theoretically provide a therapeutic
target to extend graft survival.
Whether the donor or recipient were CMV seroposi-
tive, and especially if both were seropositive, was associ-
ated with an increased probability of having at least one
episode of rapid deterioration of renal function loss be-
tween 3 and 27months after transplantation. Having a
high probability of an episode of rapid deterioration was
in turn, significantly associated with death-censored
graft loss. These associations persisted after adjusting for
eGFR at 27 months, suggesting the relationship between
episodes of rapid deterioration early in the post-
transplant period and graft loss is not mediated by hav-
ing a lower eGFR at the start of the observation/follow-
up period. These findings also suggest that CMV sero-
positivity may explain the relationship between early epi-
sodes of rapid deterioration of renal function and graft
loss, although the observational nature of our study can-
not confirm this.
Infection is a major cause of morbidity and mortality
in solid organ transplantation [18]. The risk is further in-
creased in the presence of CMV seropositivity [19], likely
due to interaction between the virus and host immune
response [20]. In anti-neutrophil cytoplasmic antibody-
associated vasculitis, a condition associated with in-
creased infection-related mortality, the presence of sub-
clinical CMV infection appeared to adversely affect the
available functional CD4+ T-cell compartment, resulting
in impaired immunity to other antigens [21]. Therefore,
a potential explanation for the association between
CMV seropositivity and episodes of rapid deterioration
may be mediated by more frequent intercurrent infec-
tions. This hypothesis cannot be addressed by this
current study but warrants further investigation.
An alternative explanation is that clinically symptom-
atic CMV infection itself, either recurrent or primary, is
associated with episodes of rapid deterioration of renal
function. However, rates of post-transplant symptomatic
CMV infection are generally low [22, 23], and have re-
duced further by 50–70% with intravenous/oral ganci-
clovir prophylaxis in trials of CMV D+ renal transplants
[24, 25]. Perhaps more common than symptomatic in-
fection are recurrent, clinically undetected episodes of
CMV reactivation. In paediatric and young adult renal
transplant cohorts, subclinical CMV infection occurred
in 22% [26], and resulted in greater odds of acute rejec-
tion, chronic allograft injury and up to 30% lower eGFR
[26, 27]. Shabir et al. [28] demonstrated that
CD4+CD28null T-cells were found predominantly in
CMV R+ kidney transplants, which, in turn, were associ-
ated with delayed graft function and poorer allograft
function at 12 months, and in vitro glomerular endothe-
lial cell injury. This, again, highlights the detrimental im-
munomodulatory effects of the CMV virus. The rates of
subclinical and symptomatic CMV infection were un-
available at the time of this analysis and would be an in-
triguing line of investigation for a future study using the
Bayesian technique.
In our cohort, an episode of acute rejection in the first
year was not associated with having an episode of rapid
decline. There were fewer patients who had acute rejec-
tion in the group who had an episode of rapid decline
compared to the group who did not, although this was not
statistically significant. A possible explanation may be that
the Bayesian methodology smoothed out sharp declines
followed by rapid, treatment-related improvement to pro-
duce averaged trajectories which did not meet the prede-
fined criteria for an episode of rapid deterioration. An
advantage of this Bayesian technique is that it smooths
out short-term variations in eGFR that might arise from
concurrent infectious episodes or dehydration episodes, or
indeed any events that could cause short-term reductions
in renal function. It, therefore, remains a possibility for
CMV seropositivity to be a contributing factor leading to
rapid deterioration of renal function through an episode
of rejection. Several studies have demonstrated this associ-
ation [29–32]. Whilst not all studies recapitulated these
findings [33], several potential CMV-associated mecha-
nisms have been described, including but not limited to
increased expression of major histocompatibility class I
and II molecules on vascular and tubular cells through
production of T-cell derived interferon-γ [34, 35], elevated
anti-endothelial cell antibodies and interleukin-2 levels
[36], and enhanced production of co-stimulatory mole-
cules on vascular endothelial, tubular epithelial and T-
cells [37, 38].
Another potential mechanism linking CMV to graft
dysfunction can be found in cardiac transplantation.
Cardiac graft vasculopathy is a major determinant of
long-term graft survival [39] and CMV infection an
established risk factor [38, 40–42]. Other studies have
shown an association between CMV and systemic ar-
teriosclerosis [43, 44], and atherosclerotic events in renal
transplant recipients [45]. Whether CMV is a significant
risk factor for renal allograft vasculopathy requires fur-
ther examination.
In our study, D+/R+ transplants had a higher odds ra-
tio than D+/R− transplants of having a probability of
rapid deterioration ≥0.8, suggesting that D+/R− trans-
plants would have a better graft survival outcome. This
is in contrast to published evidence by Leeaphorn et al.,
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reporting worse graft survival in D+/R− compared to
other serotype pairings [7]. This discrepancy may be at-
tributable to the CMV prophylaxis strategy used at our
centre during the time of transplantation (2007–2013):
only CMV D+/R− patients had valganciclovir prophy-
laxis. CMV D+/R+ patients were not treated exposing
them to the risk of CMV viraemia.
Taken together, our findings and those of Leeaphorn
et al. suggest that extending CMV prophylaxis to D−/R+
and D+/R+ pairings could potentially increase graft sur-
vival. We acknowledge, however, that our study does not
provide direct evidence to support this and further evi-
dence is required before such a change in practice is
considered. Since 2014, all CMV D+ transplants in our
centre have received valganciclovir prophylaxis in ac-
cordance with consensus guidelines [46]. Repeating our
study in a post-2014 renal transplant incident cohort
would reveal whether CMV prophylaxis improves out-
comes for patients receiving CMV seropositive kidneys.
Our study has some limitations. The analysis was
retrospective, and the available dataset was not able to
provide granular information regarding potential causes
of rapid deterioration of renal function (e.g. renal path-
ology reports, CMV viral loads, changes in immunosup-
pression). Furthermore, because of the granularity of
data required in the early observation period, patients
who were repatriated to their referring centre after their
successful kidney transplant could not be included in
this study. This could have led to some further con-
founding of our study findings and needs to be explored
in a larger subsequent study. Unfortunately, hospitals in
the United Kingdom and indeed many other countries,
have their own EHR with different levels of accessibility
and granularity of data. As such, future larger studies
will need to allow enough resource and time to allow
data to be collected from different systems and be inte-
grated for analysis. Until then, studies of the type pre-
sented here will be relatively small and limited to a
single centre. Finally, consideration may be given for the
inclusion of composite co-morbidity scores such as the
Charlson comorbidity index in future studies to reduce
other potential confounders not captured by the current
data in all-cause mortality analysis.
However, our study also has several strengths. Lever-
aging the power of EHR in our centre, we had numerous
eGFR measurements per patient and an extended
follow-up period. The use of modern Bayesian modelling
has been combined with clinically relevant and recog-
nised definition of rapid deterioration to provide a rigor-
ous assessment of renal function trajectory. It should be
recognised that there are other methods for analysing
large amounts of continuous data being developed, in-
cluding, but not limited to, joint mixed models [47].
Each of these methods have their own strengths and
weaknesses. Their use will very much depend on the
questions being considered.
Conclusion
Our study further validates the utility of using novel
statistical techniques to robustly model renal allograft
function to improve prediction of renal transplant trajec-
tory, and to better understand the factors influencing
these trajectories. Additional efforts and larger prospect-
ive studies examining renal allograft function trajectories
will be required to identify whether current efforts to
manage subclinical and occult CMV are sufficient in im-
proving long-term graft survival. The aim is to better
manage patients with specific trajectories and risk fac-
tors, and to allow more timely interventions and coun-
selling, especially if re-transplantation is a possibility.
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